Design of pharmaceutical products to meet future patient needs requires modification of current development paradigms and business models

Z Gerontol Geriatr. 2014 Jun;47(4):285-7. doi: 10.1007/s00391-014-0647-4.

Abstract

Drugs represent the most common intervention strategy for managing acute and chronic medical conditions. In light of demographic change and the increasing age of patients, the classic model of drug research and development by the pharmaceutical industry and drug prescription by physicians is reaching its limits. Different stakeholders, e.g. industry, regulatory authorities, health insurance systems, physicians etc., have at least partially differing interests regarding the process of healthcare provision. The primary responsibility for the correct handling of medication and adherence to treatment schedules lies with the recipient of a drug-based therapy, i.e. the patient. It is thus necessary to interactively involve elderly patients, as well as the other stakeholders, in the development of medication and medication application devices, and in clinical trials. This approach will provide the basis for developing a strategy that better meets patients' needs, thus resulting in improved adherence to treatment schedules and better therapeutic outcomes.

Publication types

  • Review

MeSH terms

  • Aged
  • Clinical Trials as Topic / trends*
  • Dosage Forms
  • Drug Design*
  • Drug Industry / trends*
  • Forecasting
  • Germany
  • Guideline Adherence / trends
  • Health Services Needs and Demand / trends*
  • Humans
  • Medication Adherence
  • Population Dynamics / trends*
  • Translational Research, Biomedical / trends

Substances

  • Dosage Forms